Another pill to fight obesity won US approval, pitting Lilly’s Foundayo against Novo’s Wegovy pill in the race to dominate a market worth billions. Patients and consumers may also be winners, as prices fall and selection expands. https://t.co/1upjiYnPww ...

The FDA approved Eli Lilly’s new weight-loss pill, setting up a fight with rival Novo Nordisk over the next front in the booming market https://t.co/1j0gqhoXlH ...

Eli Lilly & Co.’s weight-loss pill won US approval, ratcheting up pressure on Novo Nordisk A/S, which launched an obesity pill earlier this year. https://t.co/FDknJHod96 ...

Novo Nordisk rose as much as 4% after England's drug price regulator recommended the use of its best-selling drug Wegovy to prevent heart attacks and strokes. Wegovy is mainly a weight loss treatment but it is also approved for reducing the risk of major cardiovascular events in people living with overweight or obesity. The new recommendation the National Institute for Health and Care Excellence (NICE), England's drug price regulator, will significantly expand access to Wegovy on the country's National Heal ...

Healthcare - The UK's NICE has recommended Novo Nordisk's Wegovy (2.4mg) for reducing the risk of major cardiovascular events in adults with cardiovascular disease and obesity, marking a significant milestone for GLP-1 medications in cardiovascular prevention [2][9] - The final guidance for the treatment is expected by the end of April 2026, with plans for integration into existing NHS cardiovascular care pathways, potentially broadening the market for weight-loss drugs [3][9] Trade - The U.S. government is launching a digital refund portal for $166 billion in duties collected under the Trump administration's tariffs, following a Supreme Court ruling that deemed these tariffs unlawful [4][9] - The Treasury is adopting a "Digital Only" payment model via the ACE portal to manage the volume of claims, emphasizing the need for businesses to ensure their ACH setup is active [5] Energy & Tech - Microsoft and Engine No. 1 are in discussions for a $7 billion natural gas-fired power project in Texas, aimed at providing dedicated electricity for a large-scale data center campus [6][9] - Chevron has clarified that no commercial terms have been finalized for its participation in the project, which reflects a trend of tech companies securing energy resources for AI workloads [7] Asia-Pacific - Australia's S&P/ASX 200 index rose 1.6% to 8,618.20, supported by government signals of assistance for the private sector, including potential payment deferrals and loan restructuring [8][9] - The Australian government signed a Memorandum of Understanding with Anthropic to collaborate on AI safety and economic data tracking, marking the first arrangement under the National AI Plan [10] Commodities & Crypto - Gold prices have maintained a three-day gain amid shifting geopolitical tensions, with President Trump's comments suggesting a potential end to hostilities with Iran, leading to a drop in crude oil prices [11] - CoinShares is set to begin trading on the Nasdaq following a SPAC merger, valuing the crypto manager at approximately $1.2 billion and enhancing its presence in the U.S. market [12]

British drug-cost watchdog recommends use of Novo's Wegovy to lower heart risks | Reuters Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Wegovy presentation is displayed in New Columbia, Pennsylvania, U.S., November 13, 2023. REUTERS/Hannah Beier/Illustration/File Photo Purchase Licensing Rights, opens new tab April 1 (Reuters) - UK's drug cost-effectiveness watchdog has recommended Novo Nordisk's (NOVOb.CO), opens new tabWegovy to reduce the risk of serious h ...

Eli Lilly and Novo Nordisk, the two companies that dominate the global market for GLP-1 weight loss and diabetes drugs, are each deploying artificial intelligence (AI) across different stages of drug development in ways that are beginning to reshape how fast new medicines reach patients.By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions .Compl ...

[music] We're back on Morning Trade Live. Let's focus on Novo Nordisk, the company announcing a new drug subscription [music] plan today. More on that in a second with Marley.But the chart has been nothing short of a disaster. The stock is trading near four-year lows and is [music] down more than 75% from its all-time high in late June of 2024. Look at that.So, that's the focus of the morning trade. Joining us now for a closer look, as we promised, is Marley. Good morning, Marley.just walk us through the de ...

The company is trying to win customers by offering a "lower, predictable monthly price†for its obesity drugs. ...

Novo Nordisk (NVO) on Tuesday announced a first-of-its-kind subscription program for its weight loss therapy Wegovy (semaglutide) available on telehealth platforms, including LifeMD (LFMD) and Hims & Hers (HIMS). As part of the program, cash-paying patients can choose 3-, 6-, or 12-month subscriptions ...